CSF2 and triple-negative breast carcinoma: In addition, Greene et al’s (2015) study with 391 participants did not reveal statistically significant differences in the overall 5-year DFS rates between the AE37 + GM-CSF vaccination group and the control group.[16] However, subgroup analyses indicated trends, showcasing potential efficacy in patients with ER/progesterone receptor-negative and triple-negative breast cancer.